Neuromuscular Diseases Clinic.
Department of Neurological Emergencies.
Gac Med Mex. 2023;159(4):315-321. doi: 10.24875/GMM.M23000787.
During the COVID-19 pandemic, an increase in the number of Guillain-Barre syndrome (GBS) cases has been reported.
To describe the clinical characteristics and prognosis of patients with GBS before and during the COVID-19 pandemic.
Prospective cohort of GBS patients divided in two subgroups: before (2018-2019) and during (2020-2021) the COVID-19 pandemic. Clinical and paraclinical characteristics, as well as deaths, were recorded. A good prognosis was defined as independent ambulation recovery at three months.
Two-hundred and one patients were included (123 during and 78 before the pandemic), out of whom 69% were males; age was 45 ± 16 years, and there was 2.5% of in-hospital deaths. During the pandemic, a higher frequency of the demyelinating variant (50%), bulbar cranial nerves involvement (44% vs. 28%), prior history of vaccination (16% vs. 0%), and a lower MRC score (30 ± 16.7 vs. 34.3 ± 17.7) were documented. An increase in the number of cases was observed from July to September (38 vs. 13). There were no significant differences in independent ambulation recovery or in the number of deaths.
During the COVID-19 pandemic, a higher number of GBS cases were treated, out of which 16% were associated with the SARS-CoV-2 vaccine; patients treated during the pandemic did not have a worse prognosis.
在 COVID-19 大流行期间，报道称 Guillain-Barre 综合征（GBS）病例有所增加。
描述 COVID-19 大流行前后 GBS 患者的临床特征和预后。
前瞻性队列研究了 GBS 患者，分为两组：大流行前（2018-2019 年）和大流行期间（2020-2021 年）。记录了临床和辅助检查特征以及死亡情况。将独立行走恢复定义为预后良好。
共纳入 201 例患者（123 例在大流行期间，78 例在大流行前），其中 69%为男性；年龄为 45±16 岁，住院死亡率为 2.5%。在大流行期间，脱髓鞘变异型（50%）、颅神经受累（44%比 28%）、既往疫苗接种史（16%比 0%）和较低的 MRC 评分（30±16.7 比 34.3±17.7）更为常见。7 月至 9 月期间，病例数增加了 38 例（比 13 例增加）。独立行走恢复和死亡率无显著差异。
在 COVID-19 大流行期间，治疗的 GBS 病例数增加，其中 16%与 SARS-CoV-2 疫苗有关；在大流行期间治疗的患者预后无明显恶化。
